360b-shutterstock-com-sanofi-
360b / Shutterstock.com
12 January 2017Americas

Sanofi and Regeneron’s appeal to suspend Amgen injunction denied

A US district court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.

The injunction prevents Regeneron and Sanofi from selling their cholesterol-lowering medicine Praluent (alirocumab), which was found to infringe Amgen’s patents covering the drug Repatha (evolocumab).

Following the decision, made by the US District Court for the District of Delaware, Regeneron and Sanofi announced that they will bring the case to the US Court of Appeals for the Federal Circuit.

Regeneron said in a statement released on January 9: “We will soon file a motion with the appellate court, asking it to suspend the injunction during the appeal process.”

The court delayed the imposition of the injunction for an additional 15 days, meaning it is now due to start 45 days from January 5, in order to allow Sanofi and Regeneron time to appeal.

Amgen said in statement: “Amgen respects the court's thoughtful deliberations in a situation where a competitor made the choice to launch at risk during the pendency of a patent lawsuit within months of an expedited trial date. The company remains confident in the validity of its patents.”

The two patents which have been found to be infringed are US patent numbers 8,829,165 and 8,859,741.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
9 January 2017   Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.

More on this story

Americas
9 January 2017   Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.

More on this story

Americas
9 January 2017   Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.